BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31638925)

  • 1. Patient-derived organoids (PDOs) as a novel in vitro model for neuroblastoma tumours.
    Fusco P; Parisatto B; Rampazzo E; Persano L; Frasson C; Di Meglio A; Leslz A; Santoro L; Cafferata B; Zin A; Cimetta E; Basso G; Esposito MR; Tonini GP
    BMC Cancer; 2019 Oct; 19(1):970. PubMed ID: 31638925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours.
    Braekeveldt N; Wigerup C; Gisselsson D; Mohlin S; Merselius M; Beckman S; Jonson T; Börjesson A; Backman T; Tadeo I; Berbegall AP; Ora I; Navarro S; Noguera R; Påhlman S; Bexell D
    Int J Cancer; 2015 Mar; 136(5):E252-61. PubMed ID: 25220031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
    Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
    Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
    Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
    Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours.
    Bate-Eya LT; Ebus ME; Koster J; den Hartog IJ; Zwijnenburg DA; Schild L; van der Ploeg I; Dolman ME; Caron HN; Versteeg R; Molenaar JJ
    Eur J Cancer; 2014 Feb; 50(3):628-37. PubMed ID: 24321263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
    Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
    Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
    Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
    Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
    Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
    Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosome 10 abnormality predicts prognosis of neuroblastoma patients with bone marrow metastasis.
    Jiang CY; Xu X; Jian BL; Zhang X; Yue ZX; Guo W; Ma XL
    Ital J Pediatr; 2021 Jun; 47(1):134. PubMed ID: 34108028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 1p tumour suppressor Dnmt1-associated protein 1 regulates MYCN/ataxia telangiectasia mutated/p53 pathway.
    Yamaguchi Y; Takenobu H; Ohira M; Nakazawa A; Yoshida S; Akita N; Shimozato O; Iwama A; Nakagawara A; Kamijo T
    Eur J Cancer; 2014 May; 50(8):1555-65. PubMed ID: 24559687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A sketch of known and novel MYCN-associated miRNA networks in neuroblastoma.
    Megiorni F; Colaiacovo M; Cialfi S; McDowell HP; Guffanti A; Camero S; Felsani A; Losty PD; Pizer B; Shukla R; Cappelli C; Ferrara E; Pizzuti A; Moles A; Dominici C
    Oncol Rep; 2017 Jul; 38(1):3-20. PubMed ID: 28586032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification.
    Cohn SL; Salwen H; Quasney MW; Ikegaki N; Cowan JM; Herst CV; Kennett RH; Rosen ST; DiGiuseppe JA; Brodeur GM
    Oncogene; 1990 Dec; 5(12):1821-7. PubMed ID: 2284101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma.
    Jiang P; Huang M; Qi W; Wang F; Yang T; Gao T; Luo C; Deng J; Yang Z; Zhou T; Zou Y; Gao G; Yang X
    J Exp Clin Cancer Res; 2019 Sep; 38(1):400. PubMed ID: 31511046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells.
    Coco S; Defferrari R; Scaruffi P; Cavazzana A; Di Cristofano C; Longo L; Mazzocco K; Perri P; Gambini C; Moretti S; Bonassi S; Tonini GP
    J Pathol; 2005 Nov; 207(3):346-57. PubMed ID: 16178058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroblastoma: a multiple biological disease.
    Tonini GP
    Eur J Cancer; 1993; 29A(6):802-4. PubMed ID: 8484968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoic acid and cAMP differentially regulate human chromogranin A promoter activity during differentiation of neuroblastoma cells.
    Gaetano C; Manni I; Bossi G; Piaggio G; Soddu S; Farina A; Helman LJ; Sacchi A
    Eur J Cancer; 1995; 31A(4):447-52. PubMed ID: 7576943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.
    Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
    Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
    Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.
    Zhong ZY; Shi BJ; Zhou H; Wang WB
    J Int Med Res; 2018 Mar; 46(3):1209-1220. PubMed ID: 29322842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.